Pharmocoepigenetics: a new approach to predicting individual drug responses and targeting new drugs

被引:35
作者
Baer-Dubowska, Wanda [1 ]
Majchrzak-Celinska, Aleksandra [1 ]
Cichocki, Michal [1 ]
机构
[1] Poznan Univ Med Sci, Dept Pharmaceut Biochem, PL-60781 Poznan, Poland
关键词
epigenetics; DNA methylation; histone modification; microRNA; pharmacoepigenetics; epigenetic drugs and chemopreventive agents; ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER CELLS; HISTONE-DEACETYLASE INHIBITORS; DNA METHYLATION; GENE-EXPRESSION; INTERINDIVIDUAL DIFFERENCES; TRANSCRIPTIONAL ACTIVATION; EPIGENETIC MECHANISMS; MEMBRANE TRANSPORTERS; CHROMATIN-STRUCTURE;
D O I
10.1016/S1734-1140(11)70498-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Epigenetics is the study of heritable changes in genes and gene expression that do not involve DNA nucleotide sequences. Epigenetic modifications include DNA methylation, several forms of histone modifications, and microRNA expression. Because of its dynamic nature, epigenetics provides a link between the genome and the environment and fills the gap between DNA and proteins. Advances in epigenetics and epigenomics (the study of epigenetics on a genome-wide basis) have influenced pharmacology, leading to the development of a new specialty, pharmacoepigenetics, the study of the epigenetic basis for variations in drug response. Many genes encoding enzymes, drug transporters, nuclear receptors, and drug targets are under epigenetic control. This review describes the known epigenetic regulation of drug-metabolizing enzymes and other proteins that might affect drug response and compounds that modify the epigenetic status.
引用
收藏
页码:293 / 304
页数:12
相关论文
共 89 条
  • [1] Characterization and functional analysis of the promoter for the human equilibrative nucleoside transporter gene, hENT1
    Abdulla, Parween
    Coe, Imogen R.
    [J]. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2007, 26 (01) : 99 - 110
  • [2] The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-α (ERα) and represses ERα messenger RNA and protein expression in breast cancer cell lines
    Adams, Brian D.
    Furneaux, Henry
    White, Bruce A.
    [J]. MOLECULAR ENDOCRINOLOGY, 2007, 21 (05) : 1132 - 1147
  • [3] Differential expression of glucocorticoid receptor transcripts in major depressive disorder is not epigenetically programmed
    Alt, Simone R.
    Turner, Jonathan D.
    Klok, Melanie D.
    Meijer, Onno C.
    Lakke, Egbert A. J. F.
    DeRijk, Roel H.
    Muller, Claude P.
    [J]. PSYCHONEUROENDOCRINOLOGY, 2010, 35 (04) : 544 - 556
  • [4] Anttila S, 2003, CANCER RES, V63, P8623
  • [5] Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs
    Baker, EK
    Johnstone, RW
    Zalcberg, JR
    El-Osta, A
    [J]. ONCOGENE, 2005, 24 (54) : 8061 - 8075
  • [6] Role of Histone Deacetylases and Their Inhibitors in Cancer Biology and Treatment
    Beumer, Jan H.
    Tawbi, Hussein
    [J]. CURRENT CLINICAL PHARMACOLOGY, 2010, 5 (03): : 196 - 208
  • [7] Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells
    Bovenzi, V
    Momparler, RL
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (01) : 71 - 76
  • [8] DNA methyltransferases get connected to chromatin
    Burgers, WA
    Fuks, F
    Kouzarides, T
    [J]. TRENDS IN GENETICS, 2002, 18 (06) : 275 - 277
  • [9] Pharmacogenetics and pharmacoepigenetics of gemcitabine
    Candelaria, M.
    de la Cruz-Hernandez, E.
    Perez-Cardenas, E.
    Trejo-Becerril, C.
    Gutierrez-Hernandez, O.
    Duenas-Gonzalez, A.
    [J]. MEDICAL ONCOLOGY, 2010, 27 (04) : 1133 - 1143
  • [10] 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation:: mechanistic studies and their implications for cancer therapy
    Christman, JK
    [J]. ONCOGENE, 2002, 21 (35) : 5483 - 5495